Syndax Pharmaceuticals Stock Investor Sentiment

SNDX Stock  USD 13.04  0.09  0.69%   
Slightly above 50% of Syndax Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Syndax Pharmaceuticals suggests that some traders are interested. Syndax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syndax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.

Comfort Level 50

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Syndax Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Syndax Pharmaceuticals.

Syndax Historical Sentiment

Although Syndax Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Syndax, such as negative comments on social media and news outlets, may cause fear in the market and push Syndax Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Syndax.
  

Syndax Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Syndax Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Syndax Pharmaceuticals Historical Investor Sentiment

Investor biases related to Syndax Pharmaceuticals' public news can be used to forecast risks associated with an investment in Syndax. The trend in average sentiment can be used to explain how an investor holding Syndax can time the market purely based on public headlines and social activities around Syndax Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Syndax Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Syndax Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Syndax Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Syndax Pharmaceuticals.
over a week ago at thelincolnianonline.com         
Citigroup Lowers Syndax Pharmaceuticals Price Target to 42.00
news
over two weeks ago at finance.yahoo.com         
Syndax Q4 Earnings Snapshot
Yahoo News
over two weeks ago at seekingalpha.com         
Syndax Pharmaceuticals misses Q4 estimates initiates Q1 and FY25 outlook
seekingalpha News
over two weeks ago at gurufocus.com         
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Syndax Pharmaceuticals Reports Q4 2024 EPS of -1.10, Missing Estimates Revenue at 7.7 Million
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Syndax Pharmaceuticals Inc Reports Strong Initial Sales and Strategic Developments
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Syndax Pharmaceuticals Reports Q4 Loss, Lags Revenue Estimates
Yahoo News
over two weeks ago at seekingalpha.com         
Syndax projects 750M market opportunity for Revuforj driven by new launches and label expansions
seekingalpha News
over two weeks ago at gurufocus.com         
Earnings To Watch Syndax Pharmaceuticals Inc Reports Q4 2024 Result
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Earnings To Watch Syndax Pharmaceuticals Inc Reports Q4 2024 Result
Yahoo News
over two weeks ago at seekingalpha.com         
Syndax Pharmaceuticals Q4 2024 Earnings Preview
seekingalpha News
over two weeks ago at gurufocus.com         
Syndax Pharmaceuticals Inc Announces Upcoming Financial Results and Business Update
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Syndax Announces Participation in March Investor Conferences
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Syndax Pharmaceuticals Inc Announces Participation in Upcoming Investor Conferences
Gurufocus Stories at Macroaxis
over two weeks ago at globenewswire.com         
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and ...
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Syndax Pharmaceuticals that are available to investors today. That information is available publicly through Syndax media outlets and privately through word of mouth or via Syndax internal channels. However, regardless of the origin, that massive amount of Syndax data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Syndax Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Syndax Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Syndax Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Syndax Pharmaceuticals alpha.

Syndax Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Hemab Therapeutics Expands Management Team with Appointment of Kate Madigan, MD, as Chief Medical Officer and Announce Presentation at the 43rd Annual J.P. Morg...
01/13/2025
2
Disposition of 17428 shares by Ordentlich Peter of Syndax Pharmaceuticals at 25.8437 subject to Rule 16b-3
01/31/2025
3
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 RD Milestones
02/10/2025
4
Syndax Pharmaceuticals Inc Announces Participation in Upcoming Investor Conferences
02/25/2025
5
Syndax Pharmaceuticals Q4 2024 Earnings Preview
02/28/2025
6
Syndax Q4 Earnings Snapshot
03/03/2025
7
Decoding Syndax Pharmaceuticals Inc A Strategic SWOT Insight
03/04/2025
8
Syndax Pharmaceuticals Inc Q4 2024 Earnings Call Highlights Strong Product Launch and ...
03/05/2025
9
Whats Shaping Syndax Pharmaceuticals Growth in Biopharmaceuticals
03/06/2025
10
Acquisition by Goldan Keith A. of 23400 shares of Syndax Pharmaceuticals subject to Rule 16b-3
03/14/2025

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.